Background: Follicular cystitis is an uncommon inflammatory change in the urinary bladder wall characterized by the formation of tertiary lymphoid structures (TLSs) in the submucosa.
Objectives: To characterize clinical and pathologic features of follicular cystitis in dogs and to explore in situ distribution and possible role of Escherichia coli as an associated cause.
Animals: Eight dogs diagnosed with follicular cystitis and 2 control dogs.
Methods: Retrospective descriptive study. Dogs diagnosed with follicular cystitis (macroscopic follicular lesions in the urinary bladder mucosa and histopathologic detection of TLSs in bladder wall biopsies) were identified from medical records. Paraffin embedded bladder wall biopsies were subject to in situ hybridization for E. coli 16SrRNA identification.
Results: Follicular cystitis was diagnosed in large breed (median weight 24.9 kg, interquartile range [IQR] 18.8-35.4 kg) female dogs with a history of chronic recurrent urinary tract infections (UTIs; median duration of clinical signs 7 months, IQR 3-17 months; median number of previous UTIs 5, IQR 4-6). Positive E. coli 16SrRNA signal was detected within developing, immature and mature TLSs in 7/8 dogs, through submucosal stroma in 8/8 dogs and within the urothelium in 3/8 dogs.
Conclusions And Clinical Importance: Chronic inflammation associated with an intramural E. coli infection in the urinary bladder wall represents a possible triggering factor for the development of follicular cystitis.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10229364 | PMC |
http://dx.doi.org/10.1111/jvim.16719 | DOI Listing |
EJIFCC
December 2024
Department of Clinical Analysis, Hospital Can Misses, Eivissa, Spain.
Follicular cystitis (FC) is a chronic form of cystitis with uncertain etiology, characterized by the presence of lymphoid follicles in the bladder mucosa as a result of chronic irritation. This can be caused by various factors such as prolonged catheterization, lithiasis, recurrent urinary tract infections or neoplastic bladder pathology. Although it is a rare pathology, it is mainly seen in women over 50 years of age and manifests with nonspecific urinary symptoms such as dysuria, pollakiuria, haematuria and suprapubic pain.
View Article and Find Full Text PDFInt J Surg Case Rep
January 2025
Urology A Department, University Hospital IBN SINA, Morocco.
Introduction And Importance: Follicular cystitis (FC) is a rare inflammatory disorder of the bladder that predominantly affects women. The exact cause of FC remains largely unknown, although it has been associated with inflammatory processes and bacterial infections, particularly following urinary tract infections. Regarding orphan diseases, like follicular cystitis, where large-scale trials seem virtually impossible, case reports find their place and guide the scientific community to find the best course of action.
View Article and Find Full Text PDFExpert Opin Drug Saf
October 2024
Department of Urology, Hengyang Central Hospital, Affiliated Hengyang Hospital of Hunan Normal University, Hengyang, Hunan, China.
Background: Leuprorelin, a gonadotropin-releasing hormone agonist, is widely used to treat hormone-related disorders. This study aims to explore and analyze the safety profile of leuprorelin by examining adverse event reports from the FDA Adverse Event Reporting System (FAERS) database.
Methods: This study conducted a retrospective pharmacovigilance analysis using FAERS data from Q1 2004 to Q1 2024.
Beijing Da Xue Xue Bao Yi Xue Ban
October 2024
Department of Urology, Peking University People's Hospital; The Institute of Applied Lithotripsy Technology, Peking University, Beijing 100044, China.
Heliyon
August 2024
Department of Orthopedics, The Second Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China.
Purpose: This research focused on meticulously tracking and identifying adverse reactions associated with leuprorelin, a drug prescribed for conditions such as prostate cancer, endometriosis, uterine fibroids, and early-onset puberty. The main objective was to enhance patient safety and offer informed guidance on the appropriate use of this treatment.
Methods: From the first quarter of 2004 to the fourth quarter of 2023, a comprehensive analysis was conducted on a significant number of adverse event reports (AERs) from the FDA Adverse Event Reporting System (FAERS) database.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!